Home › Gilead Announces Phase 3 Results for an All-Oral, Sofosbuvir-Based...
 

Keywords :   


Gilead Announces Phase 3 Results for an All-Oral, Sofosbuvir-Based...

2013-11-02 15:57:50| Biotech - Topix.net

Gilead Sciences, Inc. today announced results from a Phase 3 study, PHOTON-1, evaluating the investigational once-daily nucleotide analogue sofosbuvir for the treatment of chronic hepatitis C virus infection among patients co-infected with HIV.

Tags: results phase announces gilead

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
28.09Tropical Storm Joyce Public Advisory Number 5
28.09Summary for Tropical Storm Joyce (AT1/AL112024)
28.09Post-Tropical Cyclone Helene Public Advisory Number 21
28.09Tropical Storm Joyce Forecast Discussion Number 5
28.09Tropical Storm Joyce Wind Speed Probabilities Number 5
28.09Tropical Storm Joyce Forecast Advisory Number 5
28.09Hurricane Isaac Graphics
28.09Hurricane Isaac Forecast Discussion Number 11
More »